文献速递乳腺癌放疗

老年非转移性乳腺癌患者极 weekly 局部区域大分割放疗

Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer.
PubMed 文献 · Radiother Oncol · 2021-07-15

BACKGROUND AND PURPOSE: Breast cancer locoregional (LR) radiation in the elderly requires careful consideration between the benefits of aggressive treatment and its potential toll on these patients.…

要点

  • 每周一次局部区域大分割放疗(单次>5 Gy)在老年乳腺癌患者中耐受良好。
  • 中位随访4.8年,仅1例胸壁局部复发,无区域复发,远处转移率6%。
  • 无3级及以上急性毒性,晚期毒性以1–2级为主。

核心结论

  • 极 weekly 局部区域大分割放疗耐受良好且疗效满意,是老年和虚弱患者的良好替代方案。

研究设计与样本

  • 回顾性研究,复习2011至2020年间接受辅助每周一次局部区域大分割放疗的老年乳腺癌患者病历。

主要发现

  • 中位随访4.8年,仅1例胸壁局部复发,无区域复发,远处转移率6%。
  • 5年无复发生存率80%,5年病因特异性生存率90%。
  • 3年和5年总生存率分别为69.4%和55.5%。
  • 44例(88%)患者出现1级或2级早期毒性,未登记3级及以上急性毒性。
  • 晚期毒性主要为1级或2级皮下纤维化、淋巴水肿和神经病变,仅1例患者出现3级纤维化。

临床怎么用

  • 对于老年、虚弱且不适合常规每日放疗的非转移性淋巴结阳性乳腺癌患者,可考虑每周一次局部区域大分割放疗。
  • 治疗期间需关注早期毒性,长期随访关注皮下纤维化、淋巴水肿和神经病变等晚期毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Breast cancer locoregional (LR) radiation in the elderly requires careful consideration between the benefits of aggressive treatment and its potential toll on these patients. Extreme weekly LR hypofractionated radiation (HFRT), delivering >5 Gy per fraction, may be better suited in such a population. It represents a good compromise between RT omission and exhaustive daily radiation. This study aims to report the local and LR control rate as well as the acute and long-term side effects of the elderly patients treated with HFRT in our institution, and to compare these results to those from the literature. MATERIALS AND METHODS: We conducted a retrospective study by reviewing medical records of elderly patients with breast cancer treated with adjuvant once-weekly LR HFRT between 2011 and 2020. Fifty patients presenting with primary non-metastatic node-positive breast tumors were included. Treatment outcomes including local/LR control and overall survival were reported. Early and late toxicity profiles were also assessed. RESULTS: After a median follow-up of 4.8 years, only one local recurrence in the chest wall occurred and there was no regional recurrence. The distant metastatic rate was 6%. The long-term recurrence-free survival rate was 80% at 5 years. The cause specific survival rate was 90% at 5 years. The overall survival rate was 69.4% and 55.5% at 3 and 5 years, respectively. There were 44 (88%) patients with Grade 1 or 2 early toxicity. There was no Grade 3 or higher acute toxicity registered. Late toxicity was mainly Grade 1 or 2 subcutaneous fibrosis, lymphoedema, and neuropathy except for one patient with Grade 3 fibrosis. CONCLUSION: Extreme LR HFRT is well tolerated with good outcomes and is a good alternative for elderly and frail patients. Our results confirm the efficacy and safety of such a regimen. Further randomized trials assessing both oncologic outcome and toxicity profile are justified.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Rais F, Tsui JMG, Daianska A, et al. Extreme weekly locoregional hypofractionated radiation in elderly women with non-metastatic breast cancer. Radiother Oncol. 2021. PMID: 34273468. doi:10.1016/j.radonc.2021.07.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。